DNA-based assays, including targeted gene panels and sequencing technologies, have enabled biomarker-driven therapies in many malignancies such as lung cancer (EGFR inhibitors) and melanoma (BRAF inhibitors) [100]. This evidence concerns the gene EGFR and melanoma.